The present disclosure relates generally to an ablation device. More specifically, the present disclosure pertains to an ablation device including an ionically conductive balloon for performing radio-frequency ablation therapy on body tissue.
The treatment of cardiac arrhythmias is sometimes performed in conjunction with an ablation catheter inserted into a chamber of the heart or in one of the vessels leading into or from the heart. In the treatment of atrial fibrillation, for example, a radio frequency (RF) ablation catheter equipped with a number of electrodes can be brought into contact with cardiac tissue for creating one or more ablation points along the tissue. During ablation, an RF generator supplies electrical energy to the electrodes, generating an electric field in the tissue. The resulting heat from this electric field forms a controlled lesion that blocks the electrical impulses from being conducted through the tissue and serves to promote the normal conduction of electrical impulses through the proper electrical pathway within the heart.
In certain catheter ablation procedures, it may be difficult to electrically isolate the tissue to be treated. In the treatment of paroxysmal atrial fibrillation, for example, it is often tedious and time consuming to isolate the pulmonary veins using an ablation catheter having an ablation electrode that directly contacts the tissue. Moreover, the ablations created by some ablation electrodes can cause dehydration in the tissue, which can result in scarring and calcification as the lesion heals. Due to the discrete nature of the ablation points, there is also the potential for leaving small gaps of electrically conductive tissue in the ablation line that may continue to initiate points of arrhythmias.
The present disclosure relates generally to an ablation device including an ionically conductive balloon for performing radio-frequency ablation therapy on body tissue.
In Example 1, an ablation device for treating body tissue, comprises: an elongate shaft having a proximal section, a distal section, and at least one fluid lumen configured to receive an electrically conductive fluid; an inflatable balloon coupled to the distal section of the shaft and including an interior section in fluid communication with the at least one fluid lumen for actuating the balloon between a collapsed state and an expanded state, wherein the balloon comprises a composite structure having a proximal balloon section including a first polymeric material and a distal balloon section including a second polymeric material different from the first material; and at least one electrode located within the interior space of the balloon.
In Example 2, the ablation device according to Example 1, wherein the first polymeric material is a hydrophobic polymer.
In Example 3, the ablation device according to any of Examples 1-2, wherein the second polymeric material is a hydrophilic polymer.
In Example 4, the ablation device according to any of Examples 1-3, further comprising at least one additional fluid lumen for recirculating fluid through the device.
In Example 5, the ablation device according to any of Examples 1-4, wherein, in the expanded state, the balloon is conically shaped.
In Example 6, the ablation device according to any of Examples 1-5, wherein the distal section of the balloon is invaginated.
In Example 7, the ablation device according to any of Examples 1-6, wherein the distal section of the balloon is semi-permeable.
In Example 8, the ablation device according to any of Examples 1-7, wherein a thickness of the balloon tapers along a length of the balloon from the proximal balloon section to the distal balloon section.
In Example 9, the ablation device according to any of Examples 1-8, wherein the balloon comprises a multi-layered structure.
In Example 10, the ablation device according to any of Examples 1-9, further comprising a temperature sensing element coupled to the distal section of the balloon.
In Example 11, the ablation device according to any of Examples 1-10, further comprising at least one electrocardiogram sensor coupled to the distal section of the balloon.
In Example 12, the ablation device according to any of Examples 1-11, further comprising a spring-actuated plunger assembly configured to bias the balloon in the collapsed state.
In Example 13, the ablation device according to Example 12, wherein the plunger assembly comprises a plunger mechanism and a spring configured to bias the plunger mechanism against the balloon.
In Example 14, the ablation device according to Example 13, wherein the plunger mechanism includes a plunger shaft and an atraumatic tip.
In Example 15, the ablation device according to Example 14, wherein the plunger shaft is slidably disposed within the catheter shaft and the electrode.
In Example 16, an ablation device for treating body tissue comprises: an elongate shaft having a proximal section, a distal section, and at least one fluid lumen configured to receive an electrically conductive fluid; an inflatable balloon coupled to the distal section of the shaft and including an interior section in fluid communication with the at least one fluid lumen for actuating the balloon between a collapsed state and an expanded state; at least one electrode located within the interior space of the balloon; and a spring mechanism configured to bias the balloon in the collapsed state.
In Example 17, a method of forming a balloon of an ablation catheter, the balloon having a proximal section and a distal section, the method comprising: masking the proximal section of the balloon; irradiating the distal section of the balloon with an ionizing radiation source; etching the balloon to form a plurality of micropores through the distal section of the balloon; and securing the balloon to a catheter.
In Example 18, the method according to Example 17, wherein the ionizing radiation source comprises an argon ion source.
In Example 19, the method according to any of Examples 17-18, wherein the proximal section of the balloon comprises a hydrophobic polymer and the distal section of the balloon comprises a hydrophilic polymer.
In Example 20, the method according to any of Examples 17-19, wherein a pore size of the micropores is between about 0.1 microns to 5 microns in diameter.
In Example 21, a system for ablating body tissue comprises: an RF generator including a switching mechanism operable between a first position and a second position; a fluid source including a supply of electrically conductive fluid; and an ablation device, the ablation device including an elongate shaft having a proximal section, a distal section, and at least one fluid lumen; an inflatable balloon coupled to the distal section of the shaft and including an interior section in fluid communication with the fluid source for actuating the balloon between a collapsed state and an expanded state; a first electrode disposed within the interior space of the balloon and electrically coupled to the RF generator, the first electrode configured for supplying a first RF electrical field through the balloon and into the body tissue when operating in the first position; a second electrode coupled to a distal end portion of the elongate shaft and electrically coupled to the RF generator, the second electrode configured for supplying a second RF electric field directly into the tissue when operating in the second position.
In Example 22, the system according to Example 21, wherein the balloon comprises a composite structure having a proximal balloon section including a hydrophobic polymeric material and a distal balloon section including a hydrophilic polymeric material.
In Example 23, the system according to any of Examples 21-22, wherein, in the expanded state, the balloon is conically shaped.
In Example 24, the system according to any of Examples 21-23, wherein the distal section of the balloon is invaginated.
In Example 25, the system according to any of Examples 21-24, wherein the distal section of the balloon is semi-permeable.
In Example 26, the system according to any of Examples 21-25, wherein a thickness of the balloon tapers along a length of the balloon from a proximal balloon section to a distal balloon section.
In Example 27, the system according to any of Examples 21-26, wherein the balloon comprises a multi-layered structure.
In Example 28, the system according to any of Examples 21-27, further comprising a spring-actuated plunger assembly configured to bias the balloon in the collapsed state.
In Example 29, a method for performing ablation therapy on the body of a patient comprises: advancing an ablation device to a target body tissue region, the ablation device including an inflatable balloon coupled to an elongate shaft, a first electrode disposed within an interior space of the balloon, and a second electrode located outside of the balloon; injecting an electrically conductive fluid into the interior section of the balloon and inflating the balloon from a collapsed state to an expanded state within the body; selectively energizing the first electrode and generating a first RF electrical field within the balloon interior; forming at least one ablation lesion within the body tissue using the first RF electrical field; selectively energizing the second electrode and generating a second RF electrical field; and forming at least one ablation lesion within the body tissue using the second RF electrical field.
In Example 30, the method according to Example 29, further comprising an RF generator including a switching mechanism, and wherein selectively energizing the first or second electrodes includes operating the switching mechanism between a first and second switch position.
In Example 31, the method according to any of Examples 29-30, wherein forming at least one ablation lesion within the body tissue using the first RF electrical field includes forming a lesion in the body tissue at a location distal to the elongate shaft.
In Example 32, the method according to any of Examples 29-31, wherein the at least one ablation lesion formed within the body tissue using the first RF electric field is larger than the at least one ablation lesion formed in the body tissue using the second RF electric field.
In Example 33, an ablation device for treating body tissue comprises: an elongate shaft having a proximal section, a distal section, and at least one fluid lumen configured to receive an electrically conductive fluid; an inflatable balloon coupled to the distal section of the shaft and including an interior section in fluid communication with the at least one fluid lumen for actuating the balloon between a collapsed state and an expanded state; and at least one electrode located within the interior space of the balloon, the at least one electrode configured for transmitting an RF electric field through the balloon and into body tissue in contact with the balloon; wherein the balloon is configured to transmit the RF electric field in a direction distally towards a leading end of the ablation device.
In Example 34, the ablation device according to Example 33, wherein the balloon comprises a composite structure having a proximal balloon section including a hydrophobic polymeric material and a distal balloon section including a hydrophilic polymeric material.
In Example 35, the ablation device according to any of Examples 33-34, wherein, in the expanded state, the balloon is conically shaped.
In Example 36, the ablation device according to any of Examples 33-35, wherein the distal section of the balloon is invaginated.
In Example 37, the ablation device according to any of Examples 33-36, wherein the distal section of the balloon is semi-permeable.
In Example 38, the ablation device according to any of Examples 33-37, wherein a thickness of the balloon tapers along a length of the balloon from a proximal balloon section to a distal balloon section.
In Example 39, the ablation device according to any of Examples 33-38, wherein the balloon comprises a multi-layered structure.
In Example 40, the ablation device according to any of Examples 33-39, further comprising a spring-actuated plunger assembly configured to bias the balloon in the collapsed state.
While multiple embodiments are disclosed, still other embodiments of the present invention will become apparent to those skilled in the art from the following detailed description, which shows and describes illustrative embodiments of the invention. Accordingly, the drawings and detailed description are to be regarded as illustrative in nature and not restrictive.
While the invention is amenable to various modifications and alternative forms, specific embodiments have been shown by way of example in the drawings and are described in detail below. The intention, however, is not to limit the invention to the particular embodiments described. On the contrary, the invention is intended to cover all modifications, equivalents, and alternatives falling within the scope of the invention as defined by the appended claims.
A handle 24 coupled to the proximal section 14 of the shaft 12 can be used by the clinician for manipulating and steering the distal section 16 to a target site within the body for performing an ablation. In some embodiments, the handle 24 includes a fluid port 26 and valve 28 in fluid communication with a source of electrically conductive fluid 30. In some embodiments, for example, the fluid 30 can comprise saline or a solution of saline and a fluoroscopic contrast medium that is both conductive and biocompatible. During an ablation procedure, pressurized fluid 30 can be delivered via the fluid lumen 18 to the interior of the balloon 20, causing the balloon 20 to inflate while also creating an electrical pathway between the electrode 22 and the portion of the balloon 20 in contact with the body tissue to be treated. In some embodiments, multiple fluid ports can be provided to recirculate the fluid 30 through the ablation device 10 as part of a closed-loop system for controlling the temperature within the balloon 20.
In some embodiments, the ablation device 10 further includes a steering mechanism 32 that can be used to mechanically steer the distal section 16 of the shaft 12 within the body. In certain embodiments, for example, the steering mechanism 32 comprises a slider or lever mechanism on the handle 24 that can be actuated by the clinician to engage a number of steering wires located within the shaft 12. During delivery of the device 10 to a target region within the body, the steering mechanism 32 can be engaged to deflect the distal section 16 of the shaft 12, allowing the clinician to better navigate the device 10 through the vasculature.
An RF generator 34 is configured to supply radio-frequency energy to the electrode assembly 22. In some embodiments, the device 10 is configured to operate in a bipolar mode, in which ablation energy supplied by the RF generator 34 flows from one electrode of the electrode assembly 22 to another electrode of the electrode assembly 22 or provided at a different location along the device 10 (e.g., along the distal section 16 of the shaft 12). In other embodiments, the device 10 is configured to operate in a unipolar mode, in which an indifferent electrode (e.g., an electrode patch) is attached to the patient's back or other exterior skin area and ablation energy from the RF generator 34 flows from one electrode of the assembly 22 to the indifferent electrode.
The device 10 includes at least one fluid lumen for transmitting pressurized fluid 30 to the interior space 38 of the balloon 20. In the embodiment of
In the embodiment of
When inflated with the electrically conductive fluid 30, the distal section 46b of the composite balloon 20 is rendered conductive by hydration due to the ionic content of the fluid 30 when the RF energy is supplied to the RF electrode 36. As a result, electrical current is transmitted through the fluid 30 and into the tissue in contact with the distal section 46b of the balloon 20. In some cases, current passes through all areas of the balloon material that are hydrophilic but does not pass through areas of the balloon that are hydrophobic or non-conductive.
The composite balloon structure can be formed using a number of different techniques. For example, the different sections 46a, 46b of the balloon 20 can be formed by separately dip-coating each section of the balloon 20 on a mandrel that has a defined size and shape. The balloon 20 can also be formed using other techniques, such as by spin-coating in a hollow mold or by injection or blow-molding. Another example method for constructing a composite balloon structure having a permeable or semi-permeable distal section is discussed further herein with respect to
In some embodiments, the device 10 further includes one or more temperature sensing elements that can be used to sense the temperature of fluid 30 within the balloon 20. In certain embodiments, and as shown in
In some embodiments, the temperature sensing element 48 senses the temperature of the fluid 30 contained within the interior section 38 of the balloon 20, and is connected to temperature sensing circuitry (e.g., based on a thermometer) located outside of the body. During ablation, the RF generator 34 can be controlled so as to adjust the temperature of the fluid 30 contained in the balloon 20 to a desired temperature. In those embodiments in which multiple fluid ports are utilized for recirculating fluid through the device 10, the flow of fluid can also be controlled based on feedback from the temperature sensing element 48 to maintain the fluid within the balloon 20 at a particular temperature or within a range of temperatures.
One or more electrocardiogram sensors coupled to the balloon 20 can also be used in some embodiments for sensing electrical activity in or near the heart. In the embodiment of
A spring actuated plunger assembly 56 can be used to maintain the balloon 20 in a collapsed, low-profile position to facilitate delivery of the device 10 through the body prior to inflating the balloon 20 at the desired target tissue location. In the embodiment of
In some embodiments, the plunger mechanism 58 comprises a plunger shaft 62 slidably disposed within the interior section 38 of the balloon 20 and through a portion of the RF electrode 36. The distal end of the plunger shaft 62 includes an atraumatic tip 64 which, when the plunger mechanism 58 is fully engaged distally, is configured to contact and engage the distal end 44 of the balloon 20 causing the balloon 20 to collapse and assume a low-profile position, as shown. The shape of the tip 64 is curved to conform to the shape of the balloon 20 at the distal end 44. The proximal end of the plunger shaft 62 is coupled to a plunger seal 66, which provides a surface against which the spring 60 engages the plunger shaft 62. A shoulder 68 located within the interior of the shaft 12 proximal to the spring 60 provides a proximal stop to prevent proximal movement of the spring 60 when the spring 60 is compressed.
When the tip 64 disengages from the distal end 44 of the balloon 20, and as shown in
Although the illustrative balloon 20 in
In some embodiments, the distal section 46b of the balloon 20 is semi-permeable, allowing at least some of the pressurized fluid 30 within the interior section 38 of the balloon 20 to seep into the body at or near the target ablation site. In some embodiments, the distal section 46b of the balloon 20 is permeable, allowing the pressurized fluid 30 within the interior section 38 of the balloon 20 to seep into the body at or near the target ablation site. During ablation, the presence of the electrically conductive fluid at this interface region aids in creating an electrical conduit for the electrical field generated by the RF electrode 36, and further serves to cool the ablation site. As the RF energy is applied to the RF electrode 36 inside the balloon 20, the RF energy is transmitted to the tissue in contact with the balloon 20 through the electrically conductive fluid seeping through the balloon 20. The permeability or semi-permeability of the distal section 46b also permits the delivery of an agent or drug contained within the fluid 30. In this manner, the balloon 20 may also act as a drug delivery device by introducing one or more drugs into the conductive fluid 30 and permitting the drugs to pass through the balloon 20 and into the tissue.
The balloon material or materials can be selected so as to facilitate further processing steps to create micropores through the balloon material. In some embodiments, for example, the workpiece used to create the composite balloon can be formed from a thermoplastic polymer resin such as polyethylene terephthalate (PET). The thermal and/or chemical characteristics of PET permit subsequent processing steps to be performed on the balloon while maintaining the desired tensile strength and elasticity characteristics of the balloon.
Once the composite balloon has been fabricated, the proximal, non-conductive section of the balloon is masked (block 74), and the distal (e.g., conductive) section of the balloon is irradiated with ions from an ionizing radiation source (block 76).
In one embodiment, the composite balloon is irradiated with Argon atoms from an Argon plasma source. Other suitable ionic radiation sources can also be used to irradiate the distal section of the balloon with ions.
Once irradiated, the balloon is then subjected to a sodium hydroxide (NaOH) etching process for a period of time to produce uniform micropores in the distal section of the balloon (block 78). In certain embodiments, for example, the balloon can be inserted into an etching bath and treated for a period of approximately 10 to 15 minutes until pores of a desired size are formed through the balloon material. The pore size can be controlled by the duration of the ionizing radiation and etching steps, the strength of the ionizing radiation, and the strength of the etching solution. Other factors such as the balloon composition, balloon thickness, as well as other characteristics can also affect the pore size. An example pore size that can be generated using this process can be between about 0.1 microns to about 5 microns in diameter, although other pore sizes greater or smaller are also contemplated. For example, in some cases pores can be up to 20 microns in diameter.
Once the micropores are created in the distal section of the balloon, additional processing steps can then be performed to secure the balloon onto the shaft (block 80). In one embodiment, the balloon can be mounted to the distal end of a shaft, similar to that shown in the illustrative embodiment shown in
An electrode assembly 100 disposed within the interior 94 of the balloon 90 is electrically coupled to an RF generator, and is configured to generate an RF electric field for creating controlled lesions within tissue located adjacent to the balloon 90. In some embodiments, and as shown in
In the embodiment of
When inflated with an electrically conductive fluid, the distal section 112b of the balloon 90 is rendered conductive by hydration due to the ionic content of the fluid when RF energy is supplied to the RF electrode 102. An electrical current is thus transmitted through the fluid and into the tissue in contact with the distal section 112b of the balloon 90. When inflated, the invaginated configuration of the balloon 90 also serves to direct the RF electrical field towards the distal section 112b of the balloon 90.
The ablation device 86 can further include one or more features described with respect to other embodiments, including one or more temperature sensors for sensing the temperature of fluid within or on the surface of the balloon 90, and one or more electrocardiogram sensors for sensing electrical activity in or near the heart. The device 86 can also include other features such as a spring-actuated plunger assembly. In certain embodiments, the balloon 90 can also be made permeable or semi-permeable, allowing at least some of the pressurized fluid within the interior section 94 of the balloon 90 to seep into the body at or near the target ablation site.
An electrode assembly 128 disposed within the interior 122 of the balloon 118 is electrically coupled to an RF generator, and is configured to generate an RF electric field for creating controlled lesions within tissue located adjacent to the balloon 118. In some embodiments, and as shown in
In the embodiment of
In other embodiments, the balloon 118 may transition in thickness at one or more discrete locations along the length of the balloon 118 such that the thickness of the proximal section 134a is greater than the thickness of the distal section 134b. In one embodiment, for example, the balloon 118 thickness may transition from a relatively thick configuration at the proximal portion 134a of the balloon 118 to a relatively thin configuration at the distal section 134b of the balloon 118 at a location substantially midway along the length of the balloon 118. The balloon 118 may also stepwise transition in thickness at multiple locations along the proximal and/or distal sections 134a, 136b of the balloon 118. Other configurations are also possible.
The balloon 118 can comprise a hydrophilic polymer that facilitates the transmission of the electromagnetic field generated by the RF electrode 130 through the balloon material and into contact with the tissue. In some embodiments, the balloon 118 comprises a composite structure in which multiple materials are used to transition the balloon 118 from a relatively hydrophobic composition along proximal section 134a of the balloon 118 to a relatively hydrophilic composition along the distal section 134b of the balloon 118. In some embodiments, for example, the composite balloon structure can comprise a proximal section 134a made from a hydrophobic polyurethane material and a distal section 134b made from a hydrophilic polyurethane material such as TECOPHILIC 60D®, as discussed herein. The resulting structure is a composite balloon 118 that transitions both in material composition and in thickness along the length of the balloon 118. During an ablation, this reduction in thickness, (and in some embodiments also a change in material composition) along the length of the balloon 118 causes a greater amount of the electric field generated by the RF electrode 130 to pass through the distal section 134b of the balloon 118, allowing the clinician to target body tissue that is situated distally of the balloon 118.
The ablation device 114 can further include one or more features described with respect to other embodiments herein, including one or more temperature sensors for sensing the temperature of fluid within or on the outer surface of the balloon 118 and/or one or more electrocardiogram sensors for sensing electrical activity in or near the heart. The device 114 can also include other features such as a spring-actuated plunger assembly. In certain embodiments, the balloon 118 can also be made permeable or semi-permeable, allowing at least some of the pressurized fluid within the interior section 122 of the balloon 118 to seep into the body at or near the target ablation site.
An electrode assembly 152 disposed within the interior 146 of the balloon 142 is electrically coupled to an RF generator, and is configured to generate an RF electric field for creating controlled lesions within tissue located adjacent to the balloon 142. In some embodiments, and as shown in
In the embodiment of
In some embodiments, first layer 158 has a uniform thickness along the entire length of the balloon 142. In other embodiments, the thickness of the first layer 158 may transition in thickness along the length of the balloon 142. For example, in some embodiments, the first layer 158 of the balloon 142 may taper in thickness along the length of the balloon 142 such that the portion of first layer 158 located along the proximal section 162a of the balloon 142 is thicker than the portion of the first layer 158 located along the distal section 162b. The thickness of the first layer 158 can taper either continuously or at one or more discrete locations along the length of the balloon 142. In some embodiments, the thickness of the first layer 158 may transition in thickness from about 3 mils at or near the location where the proximal end portion 156 of the balloon 142 attaches to the elongate shaft 140 to a thickness of about 1 mil at or near the distal end portion 164 of the balloon 142.
The second layer 160 of the balloon 142 comprises a hydrophobic material, and extends across only a portion of the balloon 142. In the embodiment of
In the embodiment of
During ablation, the presence of the hydrophobic second layer 160 over the first layer 158 of the balloon 142 causes a greater amount of the electrical field generated by the RF electrode 154 to pass through the distal section 162b of the balloon 142, allowing the clinician to target body tissue that is situated distally of the balloon 142. In some cases during ablation, the presence of the hydrophobic second layer 160 over the first layer 158 of the balloon 142 causes the RF current to be concentrated and evenly distributed through only the unmasked hydrophilic distal surface of the balloon, allowing the clinician to target body tissue that is situated distally of the balloon 142.
The ablation device 138 can further include one or more features described with respect to other embodiments, including one or more temperature sensors for sensing the temperature of fluid within or on the surface of the balloon and/or one or more electrocardiogram sensors for sensing electrical activity in or near the heart. The device 138 can also include other features such as a spring-actuated plunger assembly. In certain embodiments, the balloon 142 can also be made permeable or semi-permeable, allowing at least some of the pressurized fluid within the interior 146 of the balloon 142 to seep into the body at or near the target ablation site.
An electrode assembly 182 disposed within the interior 176 of the balloon 174 is electrically coupled to an RF generator 34 that can be used to generate an RF electric field for creating controlled lesions within tissue. In the embodiment of
In some embodiments, the RF generator 34 includes a switch 190 for selectively activating either the first electrode 184 or the second electrode 186. In one embodiment, and as shown, the switch 190 includes a first electrical wire 192 electrically coupled to the first electrode 184 and a second electrical wire 194 electrically coupled to the second electrode 186. During an ablation procedure, the ability to switch back and forth between the first and second electrodes 184, 186 allows the operator to adjust between providing ablation over a relatively large area via conduction through the balloon 174 or over a relatively small, focused area via the second electrode 186, which is in direct contact with the tissue and which has a smaller contact surface area than the balloon 174.
In the embodiment of
When inflated with an electrically conductive fluid, the distal section 196b of the balloon 174 is rendered conductive by hydration due to the ionic content of the fluid when the RF energy is supplied to the first RF electrode 184. As a result, electrical current is transmitted through the fluid and into the tissue in contact with the distal section 196b of the balloon 174.
The ablation device 166 can further include one or more features described with respect to other embodiments, including one or more temperature sensors for sensing the temperature of fluid within the balloon or on the surface of the balloon at the balloon-tissue interface, and one or more electrocardiogram sensors for sensing electrical activity in or near the heart. The device 166 can also include other features such as a spring-actuated plunger assembly. In certain embodiments, the balloon 174 can also be made semi-permeable, allowing at least some of the pressurized fluid within the interior section 176 the balloon 174 to seep into the body at or near the target ablation site.
To perform the therapy, a clinician inserts the ablation device 166 into the lumen of a guide catheter, and advances the ablation device 166 to a region in or near the heart to be treated (block 200). In the treatment of paroxysmal atrial fibrillation, for example, the clinician may insert the guide catheter and ablation device into a main vein or artery (e.g., a femoral artery), and advance the assembly through the vasculature into position within a heart chamber or cardiac vessel to be treated (e.g., a pulmonary vein). In some embodiments, a steering mechanism within the guide catheter or within the ablation device 166 itself can be used to steer the distal end of the device 166 into position to the desired treatment site.
Once in position, an electrically conductive fluid is then injected into the balloon 174, causing the balloon 174 to inflate (block 202). If necessary, the switch 190 on the RF generator 34 can then be set to activate the first (i.e., balloon) electrode 184 (block 204), causing energy to flow from the electrode 184 to the distal conductive section 196b of the balloon 174 through conduction through the fluid and balloon material. The clinician may then form a relatively wide lesion on the tissue by contacting the distal section 196b of the balloon 174 with the tissue (block 206).
The size and shape of the distal balloon section 196b produces a lesion that is very uniform in nature and is void of dehydrated or charred areas that can result in catheters that use an electrode in direct contact with the tissue to be ablated. In some procedures, the size and shape of the inflated balloon 174 can also facilitate forming overlapping lesions to ensure a contiguous ablation line is created and that the aberrant electrical conduction is completely blocked. In those embodiments in which the distal section 196b is also porous, a steady flow of electrically conductive fluid can be maintained throughout the ablation period, which further serves to create an electrical pathway between the balloon 174 and the body tissue.
If, during the ablation procedure, the operator desires to provide a pin-point lesion on the tissue, the switch 190 can then be set to operate using the second electrode 186 (block 208). Once set, the energy from the RF generator 34 is then transmitted to the second (i.e., tip) electrode 186, which directs RF energy directly into the tissue. In contrast to the first electrode 184, which has a relatively large surface area in contact with the tissue to be ablated, the second electrode 186 produces a smaller, focused ablation (block 210). In certain procedures, for example, the second electrode 186 can be used to generate narrow, focused ablation points whereas the first electrode 184 can be used to generate wider, less-focused ablation points. The process of switching back and forth between each of the electrodes 184, 186 can be repeated one or more times until the ablation procedure is complete.
Various modifications and additions can be made to the exemplary embodiments discussed without departing from the scope of the present invention. For example, while the embodiments described above refer to particular features, the scope of this invention also includes embodiments having different combinations of features and embodiments that do not include all of the described features. Accordingly, the scope of the present invention is intended to embrace all such alternatives, modifications, and variations as fall within the scope of the claims, together with all equivalents thereof.
This application claims priority to U.S. Provisional Application No. 61/534,587, filed Sep. 14, 2011, which is herein incorporated by reference in its entirety. This application is related to U.S. Provisional Application No. 61/534,590, entitled “Ablation Device With Multiple Ablation Modes,” filed on Sep. 14, 2011. The content of this related application is incorporated herein by reference in its entirety for all purposes.
Number | Name | Date | Kind |
---|---|---|---|
3773401 | Douklias et al. | Nov 1973 | A |
4466443 | Utsugi | Aug 1984 | A |
4602624 | Naples et al. | Jul 1986 | A |
4633882 | Matsuo et al. | Jan 1987 | A |
4732149 | Sutter | Mar 1988 | A |
4763660 | Kroll et al. | Aug 1988 | A |
4966145 | Kikumoto et al. | Oct 1990 | A |
5019076 | Yamanashi et al. | May 1991 | A |
5029588 | Yock et al. | Jul 1991 | A |
5178150 | Silverstein et al. | Jan 1993 | A |
5217460 | Knoepfler | Jun 1993 | A |
5238004 | Sahatjian et al. | Aug 1993 | A |
5240003 | Lancee et al. | Aug 1993 | A |
5254088 | Lundquist et al. | Oct 1993 | A |
5295482 | Clare et al. | Mar 1994 | A |
5318589 | Lichtman | Jun 1994 | A |
5324284 | Imran | Jun 1994 | A |
5331966 | Bennett et al. | Jul 1994 | A |
5334193 | Nardella | Aug 1994 | A |
5341807 | Nardella | Aug 1994 | A |
5377685 | Kazi et al. | Jan 1995 | A |
5383874 | Jackson et al. | Jan 1995 | A |
5385146 | Goldreyer | Jan 1995 | A |
5385148 | Lesh et al. | Jan 1995 | A |
5391199 | Ben-Haim | Feb 1995 | A |
5398683 | Edwards et al. | Mar 1995 | A |
5423811 | Imran et al. | Jun 1995 | A |
5447529 | Marchlinski et al. | Sep 1995 | A |
5462521 | Brucker et al. | Oct 1995 | A |
5482054 | Slater et al. | Jan 1996 | A |
5485849 | Panescu et al. | Jan 1996 | A |
5494042 | Panescu et al. | Feb 1996 | A |
5500012 | Brucker et al. | Mar 1996 | A |
5520683 | Subramaniam et al. | May 1996 | A |
5571088 | Lennox et al. | Nov 1996 | A |
5573535 | Viklund | Nov 1996 | A |
5575772 | Lennox | Nov 1996 | A |
5579764 | Goldreyer | Dec 1996 | A |
5582609 | Swanson et al. | Dec 1996 | A |
5647870 | Kordis et al. | Jul 1997 | A |
5718701 | Shai et al. | Feb 1998 | A |
5722402 | Swanson et al. | Mar 1998 | A |
5762067 | Dunham et al. | Jun 1998 | A |
5788636 | Curley | Aug 1998 | A |
5792064 | Panescu et al. | Aug 1998 | A |
5800482 | Pomeranz et al. | Sep 1998 | A |
5820568 | Willis | Oct 1998 | A |
5830213 | Panescu et al. | Nov 1998 | A |
5833621 | Panescu et al. | Nov 1998 | A |
5836990 | Li | Nov 1998 | A |
5868735 | Lafontaine | Feb 1999 | A |
5871483 | Jackson | Feb 1999 | A |
5871526 | Gibbs et al. | Feb 1999 | A |
5876336 | Swanson et al. | Mar 1999 | A |
5885278 | Fleischman | Mar 1999 | A |
5913856 | Chia et al. | Jun 1999 | A |
5916213 | Haissaguerre et al. | Jun 1999 | A |
5957850 | Marian et al. | Sep 1999 | A |
6004269 | Crowley et al. | Dec 1999 | A |
6027500 | Buckles et al. | Feb 2000 | A |
6050267 | Nardella et al. | Apr 2000 | A |
6050994 | Sherman | Apr 2000 | A |
6059778 | Sherman | May 2000 | A |
6063078 | Wittkampf | May 2000 | A |
6064905 | Webster, Jr. et al. | May 2000 | A |
6068629 | Haissaguerre et al. | May 2000 | A |
6070094 | Swanson et al. | May 2000 | A |
6083170 | Ben-Haim | Jul 2000 | A |
6083222 | Klein et al. | Jul 2000 | A |
6099524 | Lipson et al. | Aug 2000 | A |
6101409 | Swanson et al. | Aug 2000 | A |
6116027 | Smith et al. | Sep 2000 | A |
6120476 | Fung et al. | Sep 2000 | A |
6165123 | Thompson | Dec 2000 | A |
6171305 | Sherman | Jan 2001 | B1 |
6200314 | Sherman | Mar 2001 | B1 |
6206831 | Suorsa et al. | Mar 2001 | B1 |
6210337 | Dunham et al. | Apr 2001 | B1 |
6216027 | Willis et al. | Apr 2001 | B1 |
6224557 | Ziel et al. | May 2001 | B1 |
6233491 | Kordis et al. | May 2001 | B1 |
6241754 | Swanson et al. | Jun 2001 | B1 |
6270493 | Lalonde et al. | Aug 2001 | B1 |
6290697 | Tu et al. | Sep 2001 | B1 |
6352534 | Paddock et al. | Mar 2002 | B1 |
6400981 | Govari | Jun 2002 | B1 |
6423002 | Hossack | Jul 2002 | B1 |
6475213 | Whayne | Nov 2002 | B1 |
6488678 | Sherman | Dec 2002 | B2 |
6491710 | Satake | Dec 2002 | B2 |
6508767 | Burns et al. | Jan 2003 | B2 |
6508769 | Bonnefous | Jan 2003 | B2 |
6508803 | Horikawa et al. | Jan 2003 | B1 |
6516667 | Broad et al. | Feb 2003 | B1 |
6517533 | Swaminathan | Feb 2003 | B1 |
6517534 | McGovern et al. | Feb 2003 | B1 |
6537271 | Murray et al. | Mar 2003 | B1 |
6544175 | Newman | Apr 2003 | B1 |
6546270 | Goldin et al. | Apr 2003 | B1 |
6547788 | Maguire et al. | Apr 2003 | B1 |
6569160 | Goldin et al. | May 2003 | B1 |
6572547 | Miller et al. | Jun 2003 | B2 |
6575966 | Lane et al. | Jun 2003 | B2 |
6575969 | Rittman et al. | Jun 2003 | B1 |
6579278 | Bencini | Jun 2003 | B1 |
6582372 | Poland | Jun 2003 | B2 |
6584345 | Govari | Jun 2003 | B2 |
6589182 | Loftman et al. | Jul 2003 | B1 |
6592525 | Miller et al. | Jul 2003 | B2 |
6602242 | Fung et al. | Aug 2003 | B1 |
6620103 | Bruce et al. | Sep 2003 | B1 |
6632179 | Wilson et al. | Oct 2003 | B2 |
6638222 | Chandrasekaran et al. | Oct 2003 | B2 |
6640120 | Swanson et al. | Oct 2003 | B1 |
6647281 | Morency | Nov 2003 | B2 |
6656174 | Hegde et al. | Dec 2003 | B1 |
6658279 | Swanson et al. | Dec 2003 | B2 |
6663573 | Goldin | Dec 2003 | B2 |
6666862 | Jain et al. | Dec 2003 | B2 |
6676606 | Simpson et al. | Jan 2004 | B2 |
6692441 | Poland et al. | Feb 2004 | B1 |
6705992 | Gatzke | Mar 2004 | B2 |
6709396 | Flesch et al. | Mar 2004 | B2 |
6711429 | Gilboa et al. | Mar 2004 | B1 |
6719756 | Muntermann | Apr 2004 | B1 |
6735465 | Panescu | May 2004 | B2 |
6736814 | Manna et al. | May 2004 | B2 |
6743174 | Ng et al. | Jun 2004 | B2 |
6773402 | Govari et al. | Aug 2004 | B2 |
6776758 | Peszynski et al. | Aug 2004 | B2 |
6796979 | Lentz | Sep 2004 | B2 |
6796980 | Hall | Sep 2004 | B2 |
6804545 | Fuimaono et al. | Oct 2004 | B2 |
6811550 | Holland et al. | Nov 2004 | B2 |
6824517 | Salgo et al. | Nov 2004 | B2 |
6837884 | Woloszko | Jan 2005 | B2 |
6845257 | Fuimaono et al. | Jan 2005 | B2 |
6845264 | Skladnev et al. | Jan 2005 | B1 |
6917834 | Koblish et al. | Jul 2005 | B2 |
6922579 | Taimisto et al. | Jul 2005 | B2 |
6923808 | Taimisto | Aug 2005 | B2 |
6932811 | Hooven et al. | Aug 2005 | B2 |
6945938 | Grunwald | Sep 2005 | B2 |
6950689 | Willis et al. | Sep 2005 | B1 |
6952615 | Satake | Oct 2005 | B2 |
6958040 | Oliver et al. | Oct 2005 | B2 |
7001383 | Keidar | Feb 2006 | B2 |
7037264 | Poland | May 2006 | B2 |
7047068 | Haissaguerre | May 2006 | B2 |
7097643 | Cornelius et al. | Aug 2006 | B2 |
7099711 | Fuimaono et al. | Aug 2006 | B2 |
7105122 | Karason | Sep 2006 | B2 |
7112198 | Satake | Sep 2006 | B2 |
7115122 | Swanson et al. | Oct 2006 | B1 |
7123951 | Fuimaono et al. | Oct 2006 | B2 |
7131947 | Demers | Nov 2006 | B2 |
7166075 | Varghese et al. | Jan 2007 | B2 |
7181262 | Fuimaono et al. | Feb 2007 | B2 |
7220233 | Nita et al. | May 2007 | B2 |
7232433 | Schlesinger et al. | Jun 2007 | B1 |
7247155 | Hoey et al. | Jul 2007 | B2 |
7270634 | Scampini et al. | Sep 2007 | B2 |
7288088 | Swanson | Oct 2007 | B2 |
7291142 | Eberl et al. | Nov 2007 | B2 |
7306561 | Sathyanarayana | Dec 2007 | B2 |
7335052 | D'Sa | Feb 2008 | B2 |
7347820 | Bonnefous | Mar 2008 | B2 |
7347821 | Dkyba et al. | Mar 2008 | B2 |
7347857 | Anderson et al. | Mar 2008 | B2 |
7361144 | Levrier et al. | Apr 2008 | B2 |
7422591 | Phan | Sep 2008 | B2 |
7438714 | Phan | Oct 2008 | B2 |
7455669 | Swanson | Nov 2008 | B2 |
7488289 | Suorsa et al. | Feb 2009 | B2 |
7507205 | Borovsky et al. | Mar 2009 | B2 |
7519410 | Taimisto et al. | Apr 2009 | B2 |
7529393 | Peszynski et al. | May 2009 | B2 |
7534207 | Shehada et al. | May 2009 | B2 |
7544164 | Knowles et al. | Jun 2009 | B2 |
7549988 | Eberl et al. | Jun 2009 | B2 |
7569052 | Phan et al. | Aug 2009 | B2 |
7578791 | Rafter | Aug 2009 | B2 |
7582083 | Swanson | Sep 2009 | B2 |
7585310 | Phan et al. | Sep 2009 | B2 |
7610073 | Fuimaono et al. | Oct 2009 | B2 |
7648462 | Jenkins et al. | Jan 2010 | B2 |
7697972 | Verard et al. | Apr 2010 | B2 |
7704208 | Thiele | Apr 2010 | B2 |
7720420 | Kajita | May 2010 | B2 |
7727231 | Swanson | Jun 2010 | B2 |
7736362 | Eberl et al. | Jun 2010 | B2 |
7740629 | Anderson et al. | Jun 2010 | B2 |
7758508 | Thiele et al. | Jul 2010 | B1 |
7766833 | Lee et al. | Aug 2010 | B2 |
7776033 | Swanson | Aug 2010 | B2 |
7785324 | Eberl | Aug 2010 | B2 |
7794398 | Salgo | Sep 2010 | B2 |
7796789 | Salgo et al. | Sep 2010 | B2 |
7799025 | Wellman | Sep 2010 | B2 |
7815572 | Loupas | Oct 2010 | B2 |
7819863 | Eggers et al. | Oct 2010 | B2 |
7837624 | Hossack et al. | Nov 2010 | B1 |
7859170 | Knowles et al. | Dec 2010 | B2 |
7862561 | Swanson et al. | Jan 2011 | B2 |
7862562 | Eberl | Jan 2011 | B2 |
7879029 | Jimenez | Feb 2011 | B2 |
7892228 | Landis et al. | Feb 2011 | B2 |
7894871 | Wittkampf et al. | Feb 2011 | B2 |
7918850 | Govari et al. | Apr 2011 | B2 |
7957817 | Gillespie et al. | Jun 2011 | B1 |
7996085 | Levin | Aug 2011 | B2 |
8016822 | Swanson | Sep 2011 | B2 |
8103327 | Harlev et al. | Jan 2012 | B2 |
8128617 | Bencini et al. | Mar 2012 | B2 |
8160690 | Wilfley et al. | Apr 2012 | B2 |
8162935 | Paul et al. | Apr 2012 | B2 |
8265745 | Hauck et al. | Sep 2012 | B2 |
8267926 | Paul et al. | Sep 2012 | B2 |
8290578 | Schneider | Oct 2012 | B2 |
8317783 | Cao et al. | Nov 2012 | B2 |
8369922 | Paul et al. | Feb 2013 | B2 |
8400164 | Osadchy et al. | Mar 2013 | B2 |
8403925 | Miller et al. | Mar 2013 | B2 |
8406866 | Deno et al. | Mar 2013 | B2 |
8414579 | Kim et al. | Apr 2013 | B2 |
8449535 | Deno et al. | May 2013 | B2 |
8454538 | Wittkampf et al. | Jun 2013 | B2 |
8454589 | Deno et al. | Jun 2013 | B2 |
8489184 | Wilfley et al. | Jul 2013 | B2 |
8579889 | Bencini | Nov 2013 | B2 |
8583215 | Lichtenstein | Nov 2013 | B2 |
8603084 | Fish et al. | Dec 2013 | B2 |
8603085 | Jimenez | Dec 2013 | B2 |
8644950 | Hauck | Feb 2014 | B2 |
8657814 | Werneth et al. | Feb 2014 | B2 |
8672936 | Thao et al. | Mar 2014 | B2 |
8679109 | Paul et al. | Mar 2014 | B2 |
8728077 | Paul et al. | May 2014 | B2 |
8740900 | Kim et al. | Jun 2014 | B2 |
8755860 | Paul et al. | Jun 2014 | B2 |
8894643 | Watson et al. | Nov 2014 | B2 |
8906011 | Gelbart et al. | Dec 2014 | B2 |
8945015 | Rankin et al. | Feb 2015 | B2 |
8998890 | Paul et al. | Apr 2015 | B2 |
9089340 | Hastings et al. | Jul 2015 | B2 |
9125565 | Hauck | Sep 2015 | B2 |
9125668 | Subramaniam et al. | Sep 2015 | B2 |
9173586 | Deno et al. | Nov 2015 | B2 |
9211156 | Kim et al. | Dec 2015 | B2 |
9241687 | McGee | Jan 2016 | B2 |
9254163 | Paul et al. | Feb 2016 | B2 |
9271782 | Paul et al. | Mar 2016 | B2 |
9283026 | Paul et al. | Mar 2016 | B2 |
9393072 | Kim et al. | Jul 2016 | B2 |
20010029371 | Kordis | Oct 2001 | A1 |
20020087208 | Koblish et al. | Jul 2002 | A1 |
20020165448 | Ben-Haim et al. | Nov 2002 | A1 |
20020198521 | Maguire | Dec 2002 | A1 |
20030013958 | Govari et al. | Jan 2003 | A1 |
20030088240 | Saadat | May 2003 | A1 |
20030158548 | Phan et al. | Aug 2003 | A1 |
20030158549 | Swanson | Aug 2003 | A1 |
20030229286 | Lenker | Dec 2003 | A1 |
20040006268 | Gilboa et al. | Jan 2004 | A1 |
20040082860 | Haissaguerre | Apr 2004 | A1 |
20040092806 | Sagon et al. | May 2004 | A1 |
20040116793 | Taimisto et al. | Jun 2004 | A1 |
20040147920 | Keidar | Jul 2004 | A1 |
20040162556 | Swanson | Aug 2004 | A1 |
20040186467 | Swanson et al. | Sep 2004 | A1 |
20040210136 | Varghese et al. | Oct 2004 | A1 |
20040215177 | Swanson | Oct 2004 | A1 |
20040215186 | Cornelius et al. | Oct 2004 | A1 |
20050033331 | Burnett et al. | Feb 2005 | A1 |
20050059862 | Phan | Mar 2005 | A1 |
20050059962 | Phan | Mar 2005 | A1 |
20050059963 | Phan et al. | Mar 2005 | A1 |
20050059965 | Eberl | Mar 2005 | A1 |
20050065506 | Phan | Mar 2005 | A1 |
20050065508 | Johnson et al. | Mar 2005 | A1 |
20050070894 | McClurken | Mar 2005 | A1 |
20050090817 | Phan | Apr 2005 | A1 |
20050119545 | Swanson | Jun 2005 | A1 |
20050119648 | Swanson | Jun 2005 | A1 |
20050119649 | Swanson | Jun 2005 | A1 |
20050119653 | Swanson | Jun 2005 | A1 |
20050119654 | Swanson et al. | Jun 2005 | A1 |
20050124881 | Kanai et al. | Jun 2005 | A1 |
20050187544 | Swanson et al. | Aug 2005 | A1 |
20050203597 | Yamazaki | Sep 2005 | A1 |
20050228286 | Messerly et al. | Oct 2005 | A1 |
20050228504 | Demarais | Oct 2005 | A1 |
20050273060 | Levy et al. | Dec 2005 | A1 |
20060030919 | Mrva et al. | Feb 2006 | A1 |
20060089634 | Anderson et al. | Apr 2006 | A1 |
20060100522 | Yuan et al. | May 2006 | A1 |
20060161146 | Cornelius et al. | Jul 2006 | A1 |
20060247607 | Cornelius et al. | Nov 2006 | A1 |
20060247683 | Danek et al. | Nov 2006 | A1 |
20060253028 | Lam et al. | Nov 2006 | A1 |
20060253116 | Avitall et al. | Nov 2006 | A1 |
20070003811 | Zerfass et al. | Jan 2007 | A1 |
20070016054 | Yuan et al. | Jan 2007 | A1 |
20070016059 | Morimoto et al. | Jan 2007 | A1 |
20070016228 | Salas | Jan 2007 | A1 |
20070021744 | Creighton | Jan 2007 | A1 |
20070049925 | Phan et al. | Mar 2007 | A1 |
20070055225 | Dodd, III et al. | Mar 2007 | A1 |
20070073135 | Lee et al. | Mar 2007 | A1 |
20070088345 | Larson et al. | Apr 2007 | A1 |
20070165916 | Cloutier et al. | Jul 2007 | A1 |
20070167813 | Lee et al. | Jul 2007 | A1 |
20070181139 | Hauck | Aug 2007 | A1 |
20070238997 | Camus | Oct 2007 | A1 |
20070270794 | Anderson et al. | Nov 2007 | A1 |
20080009733 | Saksena | Jan 2008 | A1 |
20080015568 | Paul et al. | Jan 2008 | A1 |
20080025145 | Peszynski et al. | Jan 2008 | A1 |
20080051841 | Swerdlow et al. | Feb 2008 | A1 |
20080058836 | Moll et al. | Mar 2008 | A1 |
20080086073 | McDaniel | Apr 2008 | A1 |
20080091109 | Abraham | Apr 2008 | A1 |
20080140065 | Rioux et al. | Jun 2008 | A1 |
20080161705 | Podmore et al. | Jul 2008 | A1 |
20080161795 | Wang et al. | Jul 2008 | A1 |
20080161796 | Cao et al. | Jul 2008 | A1 |
20080195089 | Thiagalingam et al. | Aug 2008 | A1 |
20080228111 | Nita | Sep 2008 | A1 |
20080243214 | Koblish | Oct 2008 | A1 |
20080275428 | Tegg et al. | Nov 2008 | A1 |
20080281322 | Sherman et al. | Nov 2008 | A1 |
20080287803 | Li et al. | Nov 2008 | A1 |
20080300454 | Goto | Dec 2008 | A1 |
20080312521 | Solomon | Dec 2008 | A1 |
20080312713 | Wilfley et al. | Dec 2008 | A1 |
20090005771 | Lieber et al. | Jan 2009 | A1 |
20090030312 | Hadjicostis | Jan 2009 | A1 |
20090048591 | Ibrahim et al. | Feb 2009 | A1 |
20090056344 | Poch | Mar 2009 | A1 |
20090062790 | Malchano et al. | Mar 2009 | A1 |
20090062795 | Vakharia et al. | Mar 2009 | A1 |
20090076390 | Lee et al. | Mar 2009 | A1 |
20090093810 | Subramaniam et al. | Apr 2009 | A1 |
20090093811 | Koblish et al. | Apr 2009 | A1 |
20090099472 | Remmert et al. | Apr 2009 | A1 |
20090131932 | Vakharia et al. | May 2009 | A1 |
20090163904 | Miller et al. | Jun 2009 | A1 |
20090171341 | Pope et al. | Jul 2009 | A1 |
20090171345 | Miller et al. | Jul 2009 | A1 |
20090177069 | Razavi | Jul 2009 | A1 |
20090177111 | Miller et al. | Jul 2009 | A1 |
20090182316 | Bencini | Jul 2009 | A1 |
20090209950 | Starksen | Aug 2009 | A1 |
20090216125 | Lenker | Aug 2009 | A1 |
20090240247 | Rioux et al. | Sep 2009 | A1 |
20090259274 | Simon et al. | Oct 2009 | A1 |
20090275827 | Aiken et al. | Nov 2009 | A1 |
20090281541 | Ibrahim et al. | Nov 2009 | A1 |
20090287202 | Ingle et al. | Nov 2009 | A1 |
20090292209 | Hadjicostis | Nov 2009 | A1 |
20090299355 | Bencini et al. | Dec 2009 | A1 |
20090299360 | Ormsby | Dec 2009 | A1 |
20090306643 | Pappone et al. | Dec 2009 | A1 |
20100010487 | Phan et al. | Jan 2010 | A1 |
20100057072 | Roman et al. | Mar 2010 | A1 |
20100076402 | Mazzone | Mar 2010 | A1 |
20100094274 | Narayan et al. | Apr 2010 | A1 |
20100106155 | Anderson et al. | Apr 2010 | A1 |
20100113938 | Park et al. | May 2010 | A1 |
20100145221 | Brunnett et al. | Jun 2010 | A1 |
20100152728 | Park et al. | Jun 2010 | A1 |
20100168557 | Deno et al. | Jul 2010 | A1 |
20100168568 | Sliwa | Jul 2010 | A1 |
20100168570 | Sliwa et al. | Jul 2010 | A1 |
20100168831 | Korivi et al. | Jul 2010 | A1 |
20100241117 | Paul et al. | Sep 2010 | A1 |
20100249599 | Hastings et al. | Sep 2010 | A1 |
20100249603 | Hastings et al. | Sep 2010 | A1 |
20100249604 | Hastings et al. | Sep 2010 | A1 |
20100298826 | Leo et al. | Nov 2010 | A1 |
20100331658 | Kim et al. | Dec 2010 | A1 |
20110028820 | Lau et al. | Feb 2011 | A1 |
20110034915 | Ibrahim et al. | Feb 2011 | A1 |
20110071400 | Hastings et al. | Mar 2011 | A1 |
20110071401 | Hastings et al. | Mar 2011 | A1 |
20110112569 | Friedman et al. | May 2011 | A1 |
20110125143 | Gross et al. | May 2011 | A1 |
20110130648 | Beeckler et al. | Jun 2011 | A1 |
20110137153 | Govari et al. | Jun 2011 | A1 |
20110144491 | Sliwa et al. | Jun 2011 | A1 |
20110144524 | Fish et al. | Jun 2011 | A1 |
20110160584 | Paul et al. | Jun 2011 | A1 |
20110237933 | Cohen | Sep 2011 | A1 |
20110282249 | Tsoref et al. | Nov 2011 | A1 |
20110319782 | Sweeney et al. | Dec 2011 | A1 |
20120004547 | Harks et al. | Jan 2012 | A1 |
20120095347 | Adam et al. | Apr 2012 | A1 |
20120101398 | Ramanathan et al. | Apr 2012 | A1 |
20120116537 | Liebetanz | May 2012 | A1 |
20120136346 | Condie et al. | May 2012 | A1 |
20120136348 | Condie et al. | May 2012 | A1 |
20120136351 | Weekamp et al. | May 2012 | A1 |
20120172698 | Hastings et al. | Jul 2012 | A1 |
20120172727 | Hastings et al. | Jul 2012 | A1 |
20120172871 | Hastings et al. | Jul 2012 | A1 |
20120238897 | Wilfley et al. | Sep 2012 | A1 |
20120310064 | McGee | Dec 2012 | A1 |
20120330304 | Vegesna et al. | Dec 2012 | A1 |
20130023784 | Schneider et al. | Jan 2013 | A1 |
20130023897 | Wallace | Jan 2013 | A1 |
20130060245 | Grunewald et al. | Mar 2013 | A1 |
20130066312 | Subramaniam et al. | Mar 2013 | A1 |
20130066315 | Subramaniam et al. | Mar 2013 | A1 |
20130172715 | Just et al. | Jul 2013 | A1 |
20130172742 | Rankin et al. | Jul 2013 | A1 |
20130184706 | Gelbart et al. | Jul 2013 | A1 |
20130190747 | Koblish et al. | Jul 2013 | A1 |
20130197363 | Rankin et al. | Aug 2013 | A1 |
20130226169 | Miller et al. | Aug 2013 | A1 |
20130274582 | Afonso et al. | Oct 2013 | A1 |
20130331739 | Gertner | Dec 2013 | A1 |
20140012251 | Himmelstein et al. | Jan 2014 | A1 |
20140058375 | Koblish | Feb 2014 | A1 |
20140066764 | Subramaniam et al. | Mar 2014 | A1 |
20140073893 | Bencini | Mar 2014 | A1 |
20140075753 | Haarer et al. | Mar 2014 | A1 |
20140081111 | Tun et al. | Mar 2014 | A1 |
20140081112 | Kim et al. | Mar 2014 | A1 |
20140081113 | Cohen et al. | Mar 2014 | A1 |
20140081262 | Koblish et al. | Mar 2014 | A1 |
20140107453 | Maskara et al. | Apr 2014 | A1 |
20140107636 | Bencini | Apr 2014 | A1 |
20140194867 | Fish et al. | Jul 2014 | A1 |
20140214028 | Gelbart et al. | Jul 2014 | A1 |
20140228713 | Thao et al. | Aug 2014 | A1 |
20140276052 | Rankin et al. | Sep 2014 | A1 |
20140276811 | Koblish | Sep 2014 | A1 |
20140364843 | Paul et al. | Dec 2014 | A1 |
20150011995 | Avitall et al. | Jan 2015 | A1 |
20150133914 | Koblish | May 2015 | A1 |
20150133920 | Rankin et al. | May 2015 | A1 |
20150265341 | Koblish | Sep 2015 | A1 |
20150265348 | Avitall et al. | Sep 2015 | A1 |
20150342672 | Bencini et al. | Dec 2015 | A1 |
20150374436 | Subramaniam et al. | Dec 2015 | A1 |
20160100884 | Fay et al. | Apr 2016 | A1 |
Number | Date | Country |
---|---|---|
2682055 | Oct 2008 | CA |
1269708 | Oct 2000 | CN |
1455655 | Nov 2003 | CN |
1942145 | Apr 2007 | CN |
102271607 | Dec 2011 | CN |
102573986 | Jul 2012 | CN |
104619259 | May 2015 | CN |
104640513 | May 2015 | CN |
104661609 | May 2015 | CN |
1343426 | Sep 2003 | EP |
1343427 | Sep 2003 | EP |
1502542 | Feb 2005 | EP |
1547537 | Jun 2005 | EP |
0985423 | Apr 2006 | EP |
1717601 | Nov 2006 | EP |
1935332 | Jun 2008 | EP |
2136702 | Jul 2015 | EP |
2000000242 | Jan 2000 | JP |
200083918 | Mar 2000 | JP |
2000504242 | Apr 2000 | JP |
2002528039 | Aug 2002 | JP |
2003504090 | Feb 2003 | JP |
2004503335 | Feb 2004 | JP |
2006239414 | Sep 2006 | JP |
2007163559 | Jun 2007 | JP |
2007244857 | Sep 2007 | JP |
2009142653 | Dec 2008 | JP |
2009518150 | May 2009 | JP |
2010522623 | Jul 2010 | JP |
2011142995 | Jul 2011 | JP |
2011525842 | Sep 2011 | JP |
2012531967 | Dec 2012 | JP |
5336465 | Nov 2013 | JP |
2014012174 | Jan 2014 | JP |
2015509027 | Mar 2015 | JP |
20100021401 | Feb 2010 | KR |
101490374 | Feb 2015 | KR |
WO9221278 | Dec 1992 | WO |
WO9413358 | Jun 1994 | WO |
WO9725916 | Jul 1997 | WO |
WO9725917 | Jul 1997 | WO |
WO9736541 | Oct 1997 | WO |
9745156 | Dec 1997 | WO |
WO9858681 | Dec 1998 | WO |
9909879 | Mar 1999 | WO |
WO9927862 | Jun 1999 | WO |
WO0029062 | May 2000 | WO |
WO0158372 | Aug 2001 | WO |
WO0164145 | Sep 2001 | WO |
WO0168173 | Sep 2001 | WO |
WO0205868 | Jan 2002 | WO |
WO0209599 | Feb 2002 | WO |
WO0219934 | Mar 2002 | WO |
WO0247569 | Jun 2002 | WO |
WO02102234 | Dec 2002 | WO |
WO03039338 | May 2003 | WO |
WO2007079278 | Jul 2007 | WO |
WO2008046031 | Apr 2008 | WO |
WO2008118992 | Oct 2008 | WO |
WO2009032421 | Mar 2009 | WO |
2009048824 | Apr 2009 | WO |
2010054409 | May 2010 | WO |
WO2010056771 | May 2010 | WO |
2010082146 | Jul 2010 | WO |
2011008444 | Jan 2011 | WO |
2011033421 | Mar 2011 | WO |
WO2011024133 | Mar 2011 | WO |
WO2011089537 | Jul 2011 | WO |
2011101778 | Aug 2011 | WO |
WO2011095937 | Aug 2011 | WO |
2012001595 | Jan 2012 | WO |
WO2012001595 | Jan 2012 | WO |
WO2012049621 | Apr 2012 | WO |
WO2012066430 | May 2012 | WO |
2012161880 | Nov 2012 | WO |
WO2012151301 | Nov 2012 | WO |
2012166239 | Dec 2012 | WO |
2014072879 | May 2014 | WO |
2014152575 | Sep 2014 | WO |
2015143061 | Sep 2015 | WO |
2015183635 | Dec 2015 | WO |
Entry |
---|
Extended European Search Report issued in EP Application No. 15174537.9, issued Mar. 2, 2016, 7 pages. |
Goldberg, S. Nahum et al., “Variables Affecting Proper System Grounding for Radiofrequency Ablation in an Animal Model”, JVIR, vol. 11, No. 8, Sep. 2000, pp. 1069-1075. |
Haverkamp, W., et. al. Coagulation of Ventricular Myocardium Using Radiofrequency Alternating Current: Bio-Physical Aspects and Experimental Findings. PACE, 12:187-195, Jan. 1989, Part II. |
International Preliminary Examination Report issued in PCT/US2013/060612, completed Mar. 24, 2015, 10 pages. |
International Preliminary Report on Patentability issued in PCT/US2008/058324, mailed Sep. 29, 2009, 9 pages. |
International Preliminary Report on Patentability issued in PCT/US2013/058105, completed Mar. 10, 2015. |
International Preliminary Report on Patentability issued in PCT/US2014/027491, mailed Sep. 24, 2015, 12 pages. |
International Search Report and Written Opinion issued in PCT/US2008/058324, dated Aug. 18, 2008, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2012/031819, mailed Sep. 27, 2012, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2012/072061, mailed Mar. 21, 2013, 9 pages. |
International Search Report and Written Opinion issued in PCT/US2013/020503, mailed Mar. 20, 2013, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/021013, mailed Apr. 5, 2013, 14 pages. |
International Search Report and Written Opinion issued in PCT/US2013/056211, mailed Jan. 20, 2014. |
International Search Report and Written Opinion issued in PCT/US2013/058105, mailed Nov. 22, 2013, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060183, mailed Jan. 27, 2014, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014. |
International Search Report and Written Opinion issued in PCT/US2013/060194, mailed Jan. 29, 2014, 10 pages. |
International Search Report and Written Opinion issued in PCT/US2013/060612, mailed Feb. 28, 2014, 16 pages. |
International Search Report and Written Opinion issued in PCT/US2014/027491, mailed Sep. 23, 2014, 17 pages. |
International Search Report and Written Opinion issued in PCT/US2015/021300, mailed Jun. 9, 2015, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/055173, mailed Jan. 18, 2016, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2015/057242, mailed Jan. 15, 2016, 11 pages. |
International Search Report and Written Opinion issued in PCTUS2015/031591, mailed Aug. 17, 2015, 11 pages. |
Invitation to Pay Additional Fees and Partial International Search Report issued in PCT/US2014/027491, mailed Jul. 28, 2014, 5 pages. |
Machi MD, Junji, “Prevention of Dispersive Pad Skin Burns During RFA by a Simple Method”, Editorial Comment, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 372-373. |
Neufeld, Gordon R. et al., “Electrical Impedance Properties of the Body and the Problem of Alternate-site Burns During Electrosurgery”, Medical Instrumentation, vol. 19, No. 2, Mar.-Apr. 1985, pp. 83-87. |
Patriciu, A. et al., “Detecting Skin Burns Induced by Surface Electrodes”, published in Engineering in Medicine and Biology Society, 2001. Proceedings of the 23rd Annual International Conference of the IEEE, vol. 3, pp. 3129-3131. |
Piorkowski, Christopher et al., “First in Human Validation of Impedance-Based Catheter Tip-to-Tissue Contact Assessment in the Left Atrium”, Journal of Cardiovascular Electrophysiology, vol. 20, No. 12, Dec. 1, 2009, pp. 1366-1373. |
Pires, L. A., et. al. Temperature-guided Radiofrequency Catheter Ablation of Closed-Chest Ventricular Myocardium with a Novel Thermistor-Tipped Catheter. American Heart Journal, 127(6):1614-1618, Jun. 1994. |
Price, Adam et al., “Novel Ablation Catheter Technology that Improves Mapping Resolution and Monitoring of Lesion Maturation”, The Journal of Innovations in Cardiac Rhythm Management, vol. 3, 2002, pp. 599-609. |
Price, Adam et al., “PO3-39 Pin Electrodes Improve Resolution: Enhanced Monitoring of Radiofrequency Lesions in the Voltage and Frequency Domains”, Heart Rhythm 2010, 31st Annual Scientific Sessions, May 12-15 in Denver Colorado. |
Ring, E. R., et. al. Catheter Ablation of the Ventricular Septum with Radiofrequency Energy. American Heart Journal, 117(6):1233-1240, Jun. 1989. |
Steinke, Karin et al., “Dispersive Pad Site burns With Modern Radiofrequency Ablation Equipment”, Surg Laparosc Endosc Percutan Tech, vol. 13, No. 6, Dec. 2003, pp. 366-371. |
Zachary, J.M. et al., “PO4-86 Pin Electrodes Provide Enhanced Resolution Enabling Titration of Radiofrequency Duration to Lesion Maturation”, Heart Rythm 2011, 32 Annual Scientific Sessions, May 4-7, San Francisco, CA. |
International Preliminary Examination Report issued in PCT/US2013/060183, completed Mar. 24, 2015, 6 pages. |
International Preliminary Report on Patentabiiity issued in PCT/US2013/056211, completed Feb. 24, 2015, 5 pages. |
International Preliminary Report on Patentability issued in PCT/US2013/060194, mailed Mar. 24, 2015, 6 pages. |
International Search Report and Written Opinion issued in PCT/US2012/055309, mailed Nov. 19, 2012, 13 pages. |
Partial International Search Report issued in PCT/US2012/0551545, mailed Dec. 20, 2012, 7 pages. |
International Preliminary Report on Patentability issued in PCT/US2012/055155, issued Mar. 18, 2014, 11 pages. |
International Preliminary Report on Patentability issued in PCT/US2012/055309, issued on Mar. 18, 2014, 8 pages. |
International Search Report and Written Opinion issued in PCT/US2012/055155, mailed Mar. 11, 2013, 19 pages. |
International Preliminary Report on Patentability issued in PCT/US2015/021300 mailed Sep. 29, 2016, 7 pages. |
International Search Report and Written Opinion issued in PCT/US2015/066674, mailed Apr. 1, 2016, 11 pages. |
International Search Report and Written Opinion issued in PCT/US2016/028006 mailed Jul. 12, 2016, 12 pages. |
Number | Date | Country | |
---|---|---|---|
20130066315 A1 | Mar 2013 | US |
Number | Date | Country | |
---|---|---|---|
61534587 | Sep 2011 | US |